TTI-101 for Head and Neck Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called TTI-101 (also known as C-188-9) to determine if it can slow the growth of certain head and neck cancers not linked to HPV, a common virus. The treatment is administered before surgery to assess its potential to enhance surgical effectiveness. Individuals with stage II-IV HPV-negative squamous cell carcinoma of the head and neck who plan to undergo surgery might be suitable candidates. Participants will be randomly assigned to receive either TTI-101 or join a control group for comparison. As an Early Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but certain medications like systemic immunosuppressive drugs and recent investigational agents are not allowed. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that TTI-101 has been tested in several studies, demonstrating promising safety results. Earlier research found that TTI-101 stopped the growth of various cancers, including head and neck cancers, in animals like mice, without causing harm, suggesting it is well-tolerated.
Further studies with humans have shown that TTI-101 did not cause any major harmful effects. For instance, a study with patients who had solid tumors found that TTI-101 was safe and did not lead to significant side effects. Additionally, the treatment showed meaningful antitumor activity, which is encouraging for its potential use in cancer treatment.
This trial is in its early stages, focusing mainly on assessing safety and determining the best dosage. While early results are promising, ongoing trials are essential to fully understand the safety of TTI-101 in humans.12345Why do researchers think this study treatment might be promising?
Unlike the standard treatments for head and neck cancer, such as surgery, radiation, and chemotherapy, TTI-101 targets a specific protein involved in cancer cell growth known as STAT3. This protein plays a crucial role in the survival and proliferation of cancer cells, and by inhibiting it, TTI-101 aims to stop the cancer from growing and spreading. Researchers are excited about TTI-101 because it offers a more targeted approach, potentially leading to fewer side effects and improved outcomes compared to broader, more aggressive treatments.
What evidence suggests that TTI-101 might be an effective treatment for head and neck cancer?
Research shows that TTI-101, a new pill, targets a protein called STAT3, which is often active in many cancers, including head and neck cancer. Studies have found that TTI-101 can stop these cancers from growing in mice. Tests on people with different types of tumors showed promising results, such as partial tumor shrinkage. Additionally, TTI-101 was well-tolerated, causing no severe side effects in early tests. In this trial, participants will be randomly assigned to receive either TTI-101 or be part of a control group receiving standard care. These findings suggest that TTI-101 might help reduce the growth of head and neck cancer, especially before surgery.34678
Who Is on the Research Team?
Andrew Sikora, MD,PHD
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with Stage II-IV HPV-negative squamous cell carcinoma of the head and neck, who can swallow pills, have no distant metastases, and are planning surgery as primary therapy. Participants must not be pregnant or breastfeeding and agree to use contraception. They should have adequate organ function and no recent vaccines or major surgeries.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-surgical Treatment
Participants receive TTI-101 to assess its effect on tumor growth before standard of care surgery
Surgery
Participants undergo standard of care surgery with or without radiation
Follow-up
Participants are monitored for safety, effectiveness, and survival outcomes after treatment and surgery
What Are the Treatments Tested in This Trial?
Interventions
- Control Group
- TTI-101
Trial Overview
The study tests TTI-101's effectiveness in reducing tumor growth before standard surgery compared to a control group receiving no TTI-101. It's a randomized trial where patients are assigned by chance to either receive TTI-101 or be in the control group prior to their planned surgical treatment.
How Is the Trial Designed?
Participants you will be randomly assigned to either receive the study drug or be in a control group.
Participants you will be randomly assigned to either receive the study drug or be in a control group.
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
Tvardi Therapeutics, Inc
Collaborator
Citations
Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of ...
We conducted a phase I study of TTI-101, a first-in-class, selective small-molecule inhibitor of signal transducer and activator of transcription 3, in ...
NCT03195699 | Oral STAT3 Inhibitor, TTI-101, in Patients ...
Administration of TTI-101 to mice demonstrated that it blocked growth of cancers of the breast, head and neck, lung, and liver and it was safe when administered ...
3.
onclive.com
onclive.com/view/novel-stat3-inhibitor-tt1-101-is-safe-and-shows-antitumor-activity-in-r-r-hcc-and-other-solid-tumorsNovel STAT3 Inhibitor TT1-101 Is Safe and Shows ...
Treatment with TT1-101, was well tolerated and showed clinically meaningful antitumor activity, including confirmed partial responses (cPRs) ...
Small-molecule inhibition of STAT3 in radioresistant head ...
STAT3 activity is increased in ~50% of all cancers [10], due, in many instances, to activation of signaling molecules upstream of STAT3, including receptor ...
TTI-101: A competitive inhibitor of STAT3 that spares ...
In fact, TTI-101 administration unexpectedly reversed mechanical allodynia in models of chemotherapy-induced peripheral neuropathy (CIPN) and spared nerve ...
TTI-101 and Pembrolizumab in Treating Patients with ...
This phase I/II trial tests the safety, side effects, and best dose of STAT3 Inhibitor C-188-9 (TTI-101) and pembrolizumab for treating patients with head and ...
7.
aacrjournals.org
aacrjournals.org/clincancerres/article/31/6/965/753254/Phase-I-Trial-of-TTI-101-a-First-in-Class-OralPhase I Trial of TTI-101, a First-in-Class Oral Inhibitor of ...
The antitumor activity of TTI-101 monotherapy in patients with advanced, metastatic solid tumors is promising. A phase II study of TTI-101 in hepatocellular ...
TTI-101: A competitive inhibitor of STAT3 that spares ...
TTI-101 has shown target engagement, no toxicity, and evidence of clinical benefit in a Phase I study in patients with solid tumors. Here we report that TTI-101 ...
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.